Danaher, AstraZeneca Collaborate to Advance Diagnostic Innovation

The collaboration aims to fast-track rapid diagnostics, with Danaher’s centers supporting end-to-end development.

Danaher Corporation, a global science and technology innovator, has collaborated with AstraZeneca to develop and commercialize novel diagnostic tools and tests.

This partnership will utilize the newly opened Danaher Centers for enabling precision medicine to support a more streamlined, end-to-end development process.

Julie Sawyer Montgomery, Executive Vice President of Danaher, said, “Precision medicines are more targeted than standard therapies and thus require precision diagnostics to determine which patients are most likely to benefit. We are excited to work with AstraZeneca on the goal of creating novel tests to increase access to precision medicines, helping ensure that no patients are left behind.”

The first product intended to be developed through this partnership will leverage technologies from Leica Biosystems, one of Danaher's subsidiaries, with an initial focus on digital and computational pathology products and AI-assisted algorithms.

Leica Biosystems has developed leading digital pathology solutions, and to accelerate this digital transformation, the company recently shared its commitment to an open-access Digital Imaging and Communications in Medicine (DICOM) standard, encouraging interoperability for enhanced workflow connectivity.

Gustavo Perez-Fernandez, President of Leica Biosystems, said, “At Leica Biosystems, we've been driving the new era of digital pathology, where assays that used to be analysed by the human eye are now also analysed by digital tools, helping to improve diagnostic accuracy and therapeutic guidance.”

Leveraging its global reach and digital pathology platform, Danaher aims to deliver co-developed diagnostics worldwide, advancing precision medicine and improving outcomes, Fernandez added.

Stay tuned for more such updates on Digital Health News